Under the co-direction of Drs. Angela Caliendo and Raymond F. Schinazi, the purpose of the Virology/DrugDiscovery (VDD) Core is to provide enabling, laboratory-based approaches to promote interdisciplinary andtranslational research at Emory. Our mission, in response to Emory investigator needs, is to provide safeBiosafety level 2/3 laboratories, contemporary molecular virologic methods, and state-of-the-art drugassays to enable research on HIV prevention, treatment, and pathogenesis. The core will contribute tothe Emory CFAR action plan through the following specific aims:1. To provide economy of scale through provision of shared resources2. To facilitate academic and industrial collaborative development of HIV vaccines, and HIV prevention,therapeutic and diagnostic strategies through provision of virologic/drug discovery expertise andservices3. To promote virology & Drug Discovery education and training opportunities for CFAR investigators andlocal, national and international AIDS investigators4. To foster interdisciplinary collaboration among and between basic, clinical, and behavioral HIV/AIDSinvestigators locally, nationally and internationallyThe availability of VDD Core facilities, contemporary quantitative methods, and support staff hasenhanced the ability of Emory investigators to perform pre-clinical and clinical AIDS vaccinedevelopment and studies of HIV pathogenesis and treatment. Core capabilities will enable precisequantification of HIV, SIV, or candidate live-attenuated AIDS vaccine viruses and pharmacologicassessments of HIV therapeutics. The Core will advance studies of the treatment and prevention ofHIV, and new emerging concepts in HIV infection.
Showing the most recent 10 out of 1005 publications
